LIMITATION ON THE USE OF AMILORIDE IN EARLY RENAL-FAILURE

被引：18

作者：

KNAUF, H ^{[1
]}

REUTER, K ^{[1
]}

MUTSCHLER, E ^{[1
]}

机构：

[1] UNIV FRANKFURT,INST PHARMACOL,D-6000 FRANKFURT 70,FED REP GER

来源：

关键词：

D O I：

10.1007/BF00635709

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：61 / 66

页数：6

共 21 条

[1] KINETICS OF CANRENONE AFTER SINGLE AND MULTIPLE DOSES OF SPIRONOLACTONE
ABSHAGEN, U
BESENFELDER, E
ENDELE, R
KOCH, K
NEUBERT, B
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (04) : 255 - 262
[2] BAER JE, 1967, J PHARMACOL EXP THER, V157, P472
[3] CRAGOE EJ, 1979, AMILORIDE EPITHELIAL, P1
[4] CUTHBERT AW, 1981, EPITHELIAL ION WATER, P35
[5] DETTLI L, 1977, PROG PHARM, V1, P340
[6] AMILORIDE HANDLING IN RENAL-FAILURE
GEORGE, CF
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (01) : 94 - 95
[7] GIEBISCH G, 1976, METHODS PHARMACOLO A, V4, P121
[8] LUMINAL INFLUENCES ON POTASSIUM SECRETION - SODIUM CONCENTRATION AND FLUID-FLOW RATE
GOOD, DW
WRIGHT, FS
[J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1979, 236 (02): : F192 - F205
[9] GRAYSON MF, 1971, BRIT J PHARMACOL, V43, pP473
[10] GUSSIN RZ, 1978, J CLIN PHARM, V17, P651